Most patients receive protein replacement therapy with plasma-derived or recombinant FVIII administered i.v. The main therapeutic complication is the formation of inhibitory anti-FVIII antibodies, which develop in approximately 30% of the hemophilia A patients (4–6). The gene discussed is F8; the disease is hemophilia A.